ValuEngine lowered shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a buy rating to a hold rating in a report released on Tuesday, February 5th.
A number of other research firms have also weighed in on AERI. BidaskClub raised shares of Aerie Pharmaceuticals from a strong sell rating to a sell rating in a research report on Monday, October 15th. Mizuho restated a buy rating and issued a $77.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, November 7th. Cowen set a $105.00 target price on shares of Aerie Pharmaceuticals and gave the company a buy rating in a report on Tuesday, November 6th. Zacks Investment Research downgraded shares of Aerie Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 9th. Finally, JMP Securities set a $80.00 price objective on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, October 10th. Two analysts have rated the stock with a sell rating and twelve have issued a buy rating to the company’s stock. Aerie Pharmaceuticals currently has a consensus rating of Buy and an average price target of $75.82.
Shares of NASDAQ AERI traded up $1.25 during midday trading on Tuesday, hitting $47.92. The company had a trading volume of 497,723 shares, compared to its average volume of 681,460. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -10.31 and a beta of 1.10. Aerie Pharmaceuticals has a twelve month low of $32.18 and a twelve month high of $74.75.
In other news, insider Casey C. Kopczynski sold 11,000 shares of the company’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $46.17, for a total transaction of $507,870.00. Following the completion of the transaction, the insider now owns 97,243 shares in the company, valued at $4,489,709.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 33,000 shares of company stock valued at $1,333,090 in the last 90 days. Insiders own 10.53% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can grew its position in Aerie Pharmaceuticals by 40.2% in the 4th quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock valued at $38,000 after buying an additional 304 shares in the last quarter. Pearl River Capital LLC bought a new position in shares of Aerie Pharmaceuticals during the 4th quarter valued at about $59,000. Girard Partners LTD. bought a new position in shares of Aerie Pharmaceuticals during the 3rd quarter valued at about $105,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Aerie Pharmaceuticals by 23.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $99,000 after purchasing an additional 515 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. bought a new position in shares of Aerie Pharmaceuticals during the 4th quarter valued at about $105,000.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Story: Compound Annual Growth Rate (CAGR)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.